DetoxiGenomic Profile evaluates over 20 SNPs related to phase 1 and phase 2 detoxification pathways. These SNPS are associated with increased risk of impaired detoxification capacity especially when exposed to environmental toxins. It also identifies individuals potentially susceptible to adverse drug reactions. See sample report for list of SNPs.

• A la carte SNPs

  • ApoE - Apolipoprotein E is involved in lipid metabolism and certain polymorphisms can result in increased cardiovascular disease risk and Alzheimer's disease.1,2

  • COMT - Catechol-O-Methyltransferase polymorphisms can result in reduced enzyme activity associated with neuropsychiatric disorders, impaired estrogen metabolism, and increased sensitivity to pain.3,4

  • GSTP1 or GSTM1 - Glutathione S-Transferase polymorphisms are associated with a decreased ability to detoxify a majority of substances, which can result in oxidative stress and chronic disease risk.5

  • MTHFR (C677T, A1298C) - Methyl tetrahydrofolate Reductase - Polymorphisms of this enzyme can disrupt the metabolism of homocysteine, resulting in its accumulation as well as impaired methylation. The presence of these SNPs can increase risk of cardiovascular disease, blood vessel damage, thrombosis (blood clots), stroke, and degenerative aging.6

  • SOD2 - Superoxide Dismutase is an antioxidant enzyme and polymorphisms are associated with reduced SOD activity, increasing risk of oxidative stress.7,8

  • TNFα - Tumor Necrosis Factor-alpha is a proinflammatory cytokine and polymorphisms are associated with inflammation, oxidative stress, and numerous disease implications.9

  • VDR - Vitamin D Receptor polymorphisms are associated with decreased bone density and osteoporosis.10

• SNPs available as add-ons to other profiles including

  • NutrEval and Metabolomix+ - MTHFR, COMT, ApoE, TNF-α

  • Methylation Panel - MTHFR, COMT, CBS, MTRR, MAT1A, SHMT1, MTR, BHMT, GNMT

  • Essential Estrogens - CYP1B1, MTHFR, COMT, VDR